38
Participants
Start Date
February 29, 2000
Primary Completion Date
November 30, 2004
Study Completion Date
November 30, 2004
Post-operative adjuvant therapy
Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
neoadjuvant therapy
Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
therapeutic surgical procedure
Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
Radiation therapy with concurrent Paclitaxel
Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
Hormonal Therapy
After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
Williamson Medical Center, Frankling
Meharry Medical College, Nashville
Boston Baskin Cancer Center, Memphis
Methodist Lebonheur Healthcare, Memphis
Jackson-Madison Hospital, Jackson
Vanderbilt-Ingram Cancer Cetner, Nashville
National Cancer Institute (NCI)
NIH
Vanderbilt-Ingram Cancer Center
OTHER